vs
ADT Inc.（ADT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
ADT Inc.的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs 11.4%，领先1.3%），Revvity同比增速更快（5.9% vs 2.9%），ADT Inc.自由现金流更多（$323.5M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 2.7%）
ADT Inc.是美国头部安防企业，总部位于佛罗里达州博卡拉顿，业务覆盖美国与加拿大，为住宅、小型商户提供电子安防、消防防护及相关报警监控服务。公司2016年被阿波罗全球管理以69亿美元杠杆收购，2018年1月于纽约证券交易所上市。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ADT vs RVTY — 直观对比
营收规模更大
ADT
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出3.0%
2.9%
净利率更高
RVTY
高出1.3%
11.4%
自由现金流更多
ADT
多$161.7M
$161.8M
两年增速更快
RVTY
近两年复合增速
2.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $145.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 26.1% | 14.5% |
| 净利率 | 11.4% | 12.7% |
| 营收同比 | 2.9% | 5.9% |
| 净利润同比 | -23.5% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADTRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.3B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.2B | $649.9M |
净利润ADTRVTY
| Q4 25 | $145.4M | $98.4M | ||
| Q3 25 | $145.1M | $46.7M | ||
| Q2 25 | $165.2M | $53.9M | ||
| Q1 25 | $140.2M | $42.2M | ||
| Q4 24 | $190.0M | $94.6M | ||
| Q3 24 | $127.2M | $94.4M | ||
| Q2 24 | $92.4M | $55.4M | ||
| Q1 24 | $91.6M | $26.0M |
毛利率ADTRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率ADTRVTY
| Q4 25 | 26.1% | 14.5% | ||
| Q3 25 | 24.3% | 11.7% | ||
| Q2 25 | 26.6% | 12.6% | ||
| Q1 25 | 25.2% | 10.9% | ||
| Q4 24 | 32.4% | 16.3% | ||
| Q3 24 | 26.2% | 14.3% | ||
| Q2 24 | 23.6% | 12.4% | ||
| Q1 24 | 16.2% | 6.8% |
净利率ADTRVTY
| Q4 25 | 11.4% | 12.7% | ||
| Q3 25 | 11.2% | 6.7% | ||
| Q2 25 | 12.8% | 7.5% | ||
| Q1 25 | 11.1% | 6.4% | ||
| Q4 24 | 15.3% | 13.0% | ||
| Q3 24 | 10.2% | 13.8% | ||
| Q2 24 | 7.7% | 8.0% | ||
| Q1 24 | 7.6% | 4.0% |
每股收益（稀释后）ADTRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.8M | $919.9M |
| 总债务越低越好 | $7.4B | — |
| 股东权益账面价值 | $3.8B | $7.3B |
| 总资产 | $15.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.95× | — |
8季度趋势，按日历期对齐
现金及短期投资ADTRVTY
| Q4 25 | $80.8M | $919.9M | ||
| Q3 25 | $62.8M | $931.4M | ||
| Q2 25 | $45.2M | $991.8M | ||
| Q1 25 | $3.7M | $1.1B | ||
| Q4 24 | $96.2M | $1.2B | ||
| Q3 24 | $95.3M | $1.2B | ||
| Q2 24 | $37.9M | $2.0B | ||
| Q1 24 | $4.0M | $1.7B |
总债务ADTRVTY
| Q4 25 | $7.4B | — | ||
| Q3 25 | $7.3B | — | ||
| Q2 25 | $6.8B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.5B | — | ||
| Q3 24 | $7.5B | — | ||
| Q2 24 | $7.5B | — | ||
| Q1 24 | $7.6B | — |
股东权益ADTRVTY
| Q4 25 | $3.8B | $7.3B | ||
| Q3 25 | $3.7B | $7.4B | ||
| Q2 25 | $3.7B | $7.6B | ||
| Q1 25 | $3.6B | $7.6B | ||
| Q4 24 | $3.8B | $7.7B | ||
| Q3 24 | $3.9B | $7.9B | ||
| Q2 24 | $3.8B | $7.9B | ||
| Q1 24 | $3.7B | $7.8B |
总资产ADTRVTY
| Q4 25 | $15.8B | $12.2B | ||
| Q3 25 | $16.0B | $12.1B | ||
| Q2 25 | $16.0B | $12.4B | ||
| Q1 25 | $15.8B | $12.4B | ||
| Q4 24 | $16.1B | $12.4B | ||
| Q3 24 | $16.1B | $12.8B | ||
| Q2 24 | $16.0B | $13.4B | ||
| Q1 24 | $15.9B | $13.4B |
负债/权益比ADTRVTY
| Q4 25 | 1.95× | — | ||
| Q3 25 | 1.99× | — | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | 2.10× | — | ||
| Q4 24 | 1.98× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 2.03× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $373.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $323.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 25.4% | 21.0% |
| 资本支出强度资本支出/营收 | 3.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.57× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.7B | $509.4M |
8季度趋势，按日历期对齐
经营现金流ADTRVTY
| Q4 25 | $373.6M | $182.0M | ||
| Q3 25 | $480.1M | $138.5M | ||
| Q2 25 | $563.9M | $134.3M | ||
| Q1 25 | $466.6M | $128.2M | ||
| Q4 24 | $459.7M | $174.2M | ||
| Q3 24 | $498.2M | $147.9M | ||
| Q2 24 | $563.2M | $158.6M | ||
| Q1 24 | $363.8M | $147.6M |
自由现金流ADTRVTY
| Q4 25 | $323.5M | $161.8M | ||
| Q3 25 | $437.4M | $120.0M | ||
| Q2 25 | $526.3M | $115.5M | ||
| Q1 25 | $421.2M | $112.2M | ||
| Q4 24 | $426.0M | $149.8M | ||
| Q3 24 | $455.5M | $125.6M | ||
| Q2 24 | $516.5M | $136.6M | ||
| Q1 24 | $323.1M | $129.7M |
自由现金流率ADTRVTY
| Q4 25 | 25.4% | 21.0% | ||
| Q3 25 | 33.7% | 17.2% | ||
| Q2 25 | 40.9% | 16.0% | ||
| Q1 25 | 33.2% | 16.9% | ||
| Q4 24 | 34.3% | 20.5% | ||
| Q3 24 | 36.6% | 18.4% | ||
| Q2 24 | 42.9% | 19.7% | ||
| Q1 24 | 26.7% | 20.0% |
资本支出强度ADTRVTY
| Q4 25 | 3.9% | 2.6% | ||
| Q3 25 | 3.3% | 2.6% | ||
| Q2 25 | 2.9% | 2.6% | ||
| Q1 25 | 3.6% | 2.4% | ||
| Q4 24 | 2.7% | 3.4% | ||
| Q3 24 | 3.4% | 3.3% | ||
| Q2 24 | 3.9% | 3.2% | ||
| Q1 24 | 3.4% | 2.7% |
现金转化率ADTRVTY
| Q4 25 | 2.57× | 1.85× | ||
| Q3 25 | 3.31× | 2.97× | ||
| Q2 25 | 3.41× | 2.49× | ||
| Q1 25 | 3.33× | 3.03× | ||
| Q4 24 | 2.42× | 1.84× | ||
| Q3 24 | 3.92× | 1.57× | ||
| Q2 24 | 6.10× | 2.87× | ||
| Q1 24 | 3.97× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADT
| Recurring Monthly Revenue | $1.0B | 82% |
| Installation Revenue | $103.0M | 8% |
| Other | $89.9M | 7% |
| Other Related Services | $36.0M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
